56352
document
A prospective , randomized , double dummy , placebo-controlled trial of oral cefditoren pivoxil 400mg once daily as switch therapy after intravenous ceftriaxone in the treatment of acute pyelonephritis . OBJECTIVES To compare the clinical and bacteriological effectiveness of intravenous ( IV ) ceftriaxone followed by oral cefditoren pivoxil or IV ceftriaxone for acute pyelonephritis . METHODS A prospective randomized controlled trial of patients with a presumptive diagnosis of acute pyelonephritis was performed . Daily 2g IV ceftriaxone was initially given to all patients . After day 3 , patients who satisfied the criteria for switch therapy were randomized to either group A ( IV ceftriaxone ) or group B ( oral cefditoren pivoxil 400mg once daily ) . RESULTS Eighty-two patients were enrolled ; 41 ( 50 % ) patients in group A and 41 ( 50 % ) patients in group B were evaluated . There was no statistically significant difference in baseline characteristics between the two groups . Clinical cure was observed in 39 of 41 ( 95.1 % ) patients in group A and 41 of 41 ( 100 % ) patients in group B ( p=0.15 , 95 % confidence interval ( CI ) -0.12 to 0.02 ) . Urine bacteriological eradication was found in 63.4 % in group A and 60 % in group B ( p=0.75 , 95 % CI -0.18 to 0.25 ) . There was no statistically significant difference in adverse effects between the two treatment groups . CONCLUSION These data suggest that IV ceftriaxone followed by oral cefditoren pivoxil is highly effective and well-tolerated for the treatment of acute pyelonephritis , even for uropathogens with a high proportion of quinolone-resistant strains .
56353
Intervention_Pharmacological
cefditoren pivoxil
56354
Intervention_Pharmacological
ceftriaxone
56355
Intervention_Pharmacological
cefditoren pivoxil
56356
Intervention_Pharmacological
IV ceftriaxone
56357
Intervention_Pharmacological
2g IV ceftriaxone
56358
Intervention_Pharmacological
IV ceftriaxone
56359
Intervention_Pharmacological
oral cefditoren pivoxil 400mg
56360
Intervention_Pharmacological
ceftriaxone
56361
Intervention_Pharmacological
cefditoren pivoxil
56362
Outcome_Other
bacteriological effectiveness
56363
Outcome_Other
baseline characteristics
56364
Outcome_Physical
Clinical cure
56365
Outcome_Physical
Urine bacteriological eradication
56366
Outcome_Adverse-effects
adverse effects
56367
Outcome_Other
effective
56368
Outcome_Other
well-tolerated
56369
Participant_Condition
acute pyelonephritis
56370
Participant_Sample-size
Eighty-two
56371
Participant_Sample-size
41
56372
Participant_Sample-size
41